Anti-HIV factors: Targeting each step of HIV’s replication cycle

Current HIV Research

Volumn 14, Issue 3, 2016, Pages 175-182

  Colomer Lluch, Marta ^a   Gollahon, Lauren S ^a   Serra Moreno, Ruth ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Antiviral factors; APOBEC3G; BCA2; BST 2; Mx2; SAMHD 1; Tetherin; TRIM5

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BREAST CANCE ASSOCIATED GENE 2; BST 2; MYXOVIRUS RESISTANCE PROTEIN A; STERILE ALPHA MOTIF AND HD DOMAIN CONTAINING PROTEIN 1; TETHERIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIF PROTEIN; BST2 PROTEIN, HUMAN; CARRIER PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MX2 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; RNF115 PROTEIN, HUMAN; SAMHD1 PROTEIN, HUMAN; TRIM5 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; VIRUS REPLICATION; ANIMAL; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; APOBEC-3G DEAMINASE; CARRIER PROTEINS; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MONOMERIC GTP-BINDING PROTEINS; MYXOVIRUS RESISTANCE PROTEINS; UBIQUITIN-PROTEIN LIGASES; VIRUS REPLICATION;

EID: 84961743005     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X14999160224094621     Document Type: Article

References (116)

1. UNAIDS. How AIDS changed everything. 2015.
2. Sloan RD, Wainberg MA. Harnessing the therapeutic potential of host antiviral restriction factors that target HIV. Expert Rev Anti Infect Ther 2013; 11(1): 1-4.
3. Blanco-Melo D, Venkatesh S, Bieniasz PD. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 2012; 37(3): 399-411.
4. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427(6977): 848-53.
5. Emerman M. How TRIM5alpha defends against retroviral invasions. Proc Natl Acad Sci U S A 2006; 103(14): 5249-50.
6. Song B. TRIM5alpha. Curr Top Microbiol Immunol 2009; 339: 47-66.
7. Zhang J, Ge W, Zhan P, et al. Retroviral restriction factors TRIM5alpha: therapeutic strategy to inhibit HIV-1 replication. Curr Med Chem 2011; 18(17): 2649-54.
8. Javanbakht H, Diaz-Griffero F, Stremlau M, et al. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J Biol Chem 2005; 280(29): 26933-40.
9. Li X, Sodroski J. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higherorder self-association. J Virol 2008; 82(23): 11495-502.
10. Diaz-Griffero F, Kar A, Perron M, et al. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J Virol 2007; 81(19): 10362-78.
11. Diaz-Griffero F, Qin XR, Hayashi F, et al. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J Virol 2009; 83(20): 10737-51.
12. Stremlau M, Perron M, Lee M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 2006; 103(14): 5514-9.
13. Perez-Caballero D, Hatziioannou T, Zhang F, et al. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005; 79(24): 15567-72.
14. Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011; 472(7343): 361-5.
15. Uchil PD, Hinz A, Siegel S, et al. TRIM protein mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol 2013; 87(1): 257-72.
16. Owens CM, Yang PC, Gottlinger H, et al. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 2003; 77(1): 726-31.
17. Hatziioannou T, Cowan S, Von Schwedler UK, et al. Speciesspecific tropism determinants in the human immunodeficiency virus type 1 capsid. J Virol 2004; 78(11): 6005-12.
18. Ikeda Y, Ylinen LM, Kahar-Bador M, et al. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 2004; 78(21): 11816-22.
19. Langelier CR, Sandrin V, Eckert DM, et al. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol 2008; 82(23): 11682-94.
20. Anderson J, Akkina R. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther 2008; 19(3): 217-28.
21. Li Y, Li X, Stremlau M, et al. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol 2006; 80(14): 6738-44.
22. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474(7353): 658-61.
23. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474(7353): 654-7.
24. Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012; 13(3): 223-8.
25. Powell RD, Holland PJ, Hollis T, et al. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTPregulated deoxynucleotide triphosphohydrolase. J Biol Chem 2011; 286(51): 43596-600.
26. Goldstone DC, Ennis-Adeniran V, Hedden JJ, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480(7377): 379-82.
27. Goncalves A, Karayel E, Rice GI, et al. SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutieres syndrome-associated mutations. Hum Mutat 2012; 33(7): 1116-22.
28. Tungler V, Staroske W, Kind B, et al. Single-stranded nucleic acids promote SAMHD1 complex formation. J Mol Med (Berl) 2013; 91(6): 759-70.
29. Beloglazova N, Flick R, Tchigvintsev A, et al. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J Biol Chem 2013; 288(12): 8101-10.
30. Ryoo J, Choi J, Oh C, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med 2014; 20(8): 936-41.
31. Ahn J, Hao C, Yan J, et al. HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J Biol Chem 2012; 287(15): 12550-8.
32. Ballana E, Badia R, Terradas G, et al. SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob Agents Chemother 2014; 58(8): 4804-13.
33. Martin A, Bardwell PD, Woo CJ, et al. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 2002; 415(6873): 802-6.
34. Bishop KN, Holmes RK, Sheehy AM, et al. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14(15): 1392-6.
35. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-9.
36. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103.
37. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-8.
38. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003; 13(22): 2009-13.
39. Liu B, Yu X, Luo K, et al. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78(4): 2072-81.
40. Marin M, Rose KM, Kozak SL, et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9(11): 1398-403.
41. Mehle A, Strack B, Ancuta P, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279: 7792-8.
42. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 vif. Nat Med 2003; 9: 1404-7.
43. Stopak K, Noronha CD, Yonemoto W, et al. HIV-1 vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12: 591-601.
44. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 vif-cul5-SCF complex. Science 2003; 302: 1056-60.
45. Iwatani Y, Chan DS, Liu L, et al. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci U S A 2009; 106(46): 19539-44.
46. Miyakawa K, Matsunaga S, Kanou K, et al. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction. Nat Commun 2015; 6: 6945.
47. Zuo T, Liu D, Lv W, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J Virol 2012; 86(10): 5497-507.
48. Huang W, Zuo T, Luo X, et al. Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Chem Biol Drug Des 2013; 81(6): 730-41.
49. Huang W, Zuo T, Jin H, et al. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Mol Divers 2013; 17(2): 221-43.
50. Zhang S, Zhong L, Chen B, et al. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex. Antiviral Res 2015; 122: 20-7.
51. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012; 287(49): 40875-83.
52. Harris RS. Enhancing immunity to HIV through APOBEC. Nat Biotechnol 2008; 26(10): 1089-90.
53. Pillai SK, Wong JK, Barbour JD. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 2008; 5: 26.
54. Goujon C, Moncorge O, Bauby H, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013; 502(7472): 559-62.
55. Kane M, Yadav SS, Bitzegeio J, et al. MX2 is an interferoninduced inhibitor of HIV-1 infection. Nature 2013; 502(7472): 563-6.
56. Liu Z, Pan Q, Ding S, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 2013; 14(4): 398-410.
57. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011; 31(1): 79-87.
58. Gao S, von der Malsburg A, Dick A, et al. Structure of myxovirus resistance protein a reveals intra-and intermolecular domain interactions required for the antiviral function. Immunity 2011; 35(4): 514-25.
59. Mitchell PS, Patzina C, Emerman M, et al. Evolution-guided identification of antiviral specificity determinants in the broadly acting interferon-induced innate immunity factor MxA. Cell Host Microbe 2012; 12(4): 598-604.
60. Haller O, Staeheli P, Schwemmle M, et al. Mx GTPases: dynaminlike antiviral machines of innate immunity. Trends Microbiol 2015.
61. Asano A, Jin HK, Watanabe T. Mouse Mx2 gene: organization, mRNA expression and the role of the interferon-response promoter in its regulation. Gene 2003; 306: 105-13.
62. Gerardin JA, Baise EA, Pire GA, et al. Genomic structure, organisation, and promoter analysis of the bovine (Bos taurus) Mx1 gene. Gene 2004; 326: 67-75.
63. Hug H, Costas M, Staeheli P, et al. Organization of the murine Mx gene and characterization of its interferon-and virus-inducible promoter. Mol Cell Biol 1988; 8(8): 3065-79.
64. Gao S, von der Malsburg A, Paeschke S, et al. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature 2010; 465(7297): 502-6.
65. Pitossi F, Blank A, Schroder A, et al. A functional GTP-binding motif is necessary for antiviral activity of Mx proteins. J Virol 1993; 67(11): 6726-32.
66. Ponten A, Sick C, Weeber M, et al. Dominant-negative mutants of human MxA protein: domains in the carboxy-terminal moiety are important for oligomerization and antiviral activity. J Virol 1997; 71(4): 2591-9.
67. Melen K, Keskinen P, Ronni T, et al. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 1996; 271(38): 23478-86.
68. King MC, Raposo G, Lemmon MA. Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB. Proc Natl Acad Sci U S A 2004; 101(24): 8957-62.
69. Fricke T, White TE, Schulte B, et al. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology 2014; 11: 68.
70. Goujon C, Moncorge O, Bauby H, et al. Transfer of the aminoterminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol 2014; 88(16): 9017-26.
71. Busnadiego I, Kane M, Rihn SJ, et al. Host and viral determinants of Mx2 antiretroviral activity. J Virol 2014; 88(14): 7738-52.
72. Strebel K, Klimkait T, Maldarelli F, et al. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989; 63: 3784-91.
73. Terwilliger EF, Cohen EA, Lu Y, et al. Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A 1989; 86: 5163-7.
74. Klimkait T, Strebel K, Hoggan MD, et al. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990; 64: 621-9.
75. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177): 425-30.
76. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3(4): 245-52.
77. Kupzig S, Korolchuk V, Rollason R, et al. Bst-2/HM1.24 is a raftassociated apical membrane protein with an unusual topology. Traffic 2003; 4: 694-709.
78. Erikson E, Adam T, Schmidt S, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A 2011; 108(33): 13688-93.
79. Rollason R, Korolchuk V, Hamilton C, et al. Clatharin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007; 120: 3850-058.
80. Cimarelli A, Darlix JL. Assembling the human immunodeficiency virus type 1. Cell Mol Life Sci 2002; 59(7): 1166-84.
81. Evans DT, Serra-Moreno R, Singh RK, et al. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 2010; 18(9): 388-96.
82. Perez-Caballero D, Zang T, Ebrahimi A, et al. Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell 2009; 139(3): 499-511.
83. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83(4): 1837-44.
84. Mansouri M, Viswanathan K, Douglas JL, et al. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009; 83(19): 9672-81.
85. Sakuma T, Noda T, Urata S, et al. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009; 83(5): 2382-5.
86. Jia B, Serra-Moreno R, Neidermyer W, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009; 5(5): e1000429.
87. Zhang F, Wilson SJ, Landford WC, et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009; 6(1): 54-67.
88. Sauter D, Schindler M, Specht A, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009; 6(5): 409-21.
89. Serra-Moreno R, Zimmermann K, Stern LJ, et al. Tetherin/BST-2 Antagonism by Nef Depends on a Direct Physical Interaction between Nef and Tetherin, and on Clathrin-mediated Endocytosis. PLoS Pathog 2013; 9(7): e1003487.
90. Kluge SF, Mack K, Iyer SS, et al. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe 2014; 16(5): 639-50.
91. Le Tortorec A, Neil SJ. Antagonism and intracellular sequestration of human tetherin by the HIV-2 envelope glycoprotein. J Virol 2009; 83(22): 11966-78.
92. Iwabu Y, Fujita H, Kinomoto M, et al. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009; 284(50): 35060-72.
93. Douglas JL, Viswanathan K, McCarroll MN, et al. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009; 83(16): 7931-47.
94. Mangeat B, Gers-Huber G, Lehmann M, et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009; 5(9): e1000574.
95. Mitchell RS, Katsura C, Skasko MA, et al. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endolysosomal trafficking. PLoS Pathog 2009; 5(5): e1000450.
96. Tervo HM, Homann S, Ambiel I, et al. beta-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 2011; 8: 9.
97. Dube M, Roy BB, Guiot-Guillain P, et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010; 6(4): e1000856.
98. Cocka LJ, Bates P. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 2012; 8(9): e1002931.
99. Serra-Moreno R, Jia B, Breed M, et al. Compensatory Changes in the Cytoplasmic Tail of gp41 Confer Resistance to Tetherin/BST-2 in a Pathogenic Nef-Deleted SIV. Cell Host Microbe 2011; 9(1): 46-57.
100. Gupta RK, Mlcochova P, Pelchen-Matthews A, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A 2009; 106(49): 20889-94.
101. Galao RP, Le Tortorec A, Pickering S, et al. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 2012; 12(5): 633-44.
102. Tokarev A, Suarez M, Kwan W, et al. Stimulation of NF-kB Activity by the HIV Restriction Factor BST2. J Virol 2013; 87(4): 2046-57.
103. Galao RP, Pickering S, Curnock R, et al. Retroviral Retention Activates a Syk-Dependent HemITAM in Human Tetherin. Cell Host Microbe 2014; 16(3): 291-303.
104. Postler TS, Desrosiers RC. The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-kappaB activation through TGFbeta-activated kinase 1. Cell Host Microbe 2012; 11(2): 181-93.
105. Burger A, Li H, Zhang XK, et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene 1998; 16(3): 327-33.
106. Amemiya Y, Azmi P, Seth A. Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res 2008; 6(9): 1385-96.
107. Connor MK, Azmi PB, Subramaniam V, et al. Molecular characterization of ring finger protein 11. Mol Cancer Res 2005; 3(8): 453-61.
108. Burger AM, Gao Y, Amemiya Y, et al. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 2005; 65(22): 10401-12.
109. Miyakawa K, Ryo A, Murakami T, et al. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 2009; 5(12): e1000700.
110. Mizuno K, Kitamura A, Sasaki T. Rabring7, a novel Rab7 target protein with a RING finger motif. Mol Biol Cell 2003; 14(9): 3741-52.
111. Nityanandam R, Serra-Moreno R. BCA2/Rabring7 targets HIV-1 Gag for lysosomal degradation in a tetherin-independent manner. PLoS Pathog 2014; 10(5): e1004151.
112. Aguilar-Hernandez V, Medina J, Aguilar-Henonin L, et al. Expansion and diversification of BTL ring-H2 ubiquitin ligases in angiosperms: putative Rabring7/BCA2 orthologs. PLoS One 2013; 8(8): e72729.
113. Burger AM, Kona F, Amemiya Y, et al. Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer. Open Cancer J 2010; 3(1): 116-23.
114. Burger A, Amemiya Y, Kitching R, et al. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 2006; 8(8): 689-95.
115. The human protein atlas. Tissue distribution RNF115 [cited 2015 June 19th]; Available from: http://www.proteinatlas.org/search/RN F115.
116. Zhang DL, Yu DH, Chen J, et al. Characterization and expression analysis of BCA2 gene in large yellow croaker, Larimichthys crocea. Fish Shellfish Immunol 2015; 46(2): 543-9.